Michael Flisak, DO
Interventional Cardiology · Michigan City, INNPI 1548426943
Payments from drug & device makers
Across 95 payments — averaging $118.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$8K
- Abbott$1K
- AstraZeneca$228
- Medtronic$209
- Boehringer Ingelheim$197
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$185
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$6,50058%
- Travel & lodging$2,26220%
- Food & beverage$2,46822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 21 | $8,153 |
| Abbott | 6 | $1,074 |
| AstraZeneca | 9 | $228 |
| Medtronic(2 entities) | 8 | $209 |
| Boehringer Ingelheim | 3 | $197 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $185 |
| Cardiovascular Systems Inc. | 2 | $164 |
| Lantheus Medical Imaging, Inc. | 2 | $160 |
| Johnson & Johnson | 9 | $146 |
| Bard Peripheral Vascular, Inc. | 7 | $117 |
| Philips North America LLC | 2 | $95 |
| Angiodynamics, Inc. | 1 | $83 |
| Pfizer | 3 | $82 |
| Novartis | 4 | $56 |
| Abiomed | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Gilead | 2 | $25 |
| Merit Medical Systems Inc | 1 | $25 |
| Novo Nordisk | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Amgen | 1 | $18 |
| Livanova USA, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Inari Medical, Inc. | 1 | $15 |
| EKOS Corporation | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANGIOJET$4,366
- GENERAL - THERAPIES$3,470
- PERCLOSE PROGLIDE$793
- Peripheral Orbital Atherectomy System$120
- JARDIANCE$114
- GALLANT$109
- FARXIGA$108
How this compares
$11,230 in reported general payments places this provider in the 60th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $112,858 |
| JardianceEmpagliflozin | 58 | $56,455 |
| XareltoRivaroxaban | 48 | $39,593 |
| EntrestoSacubitril/Valsartan | 30 | $27,514 |
| BrilintaTicagrelor | 13 | $5,914 |
| ClopidogrelClopidogrel Bisulfate | 134 | $2,388 |
| Metoprolol Succinate | 139 | $2,030 |
| Atorvastatin Calcium | 173 | $1,816 |
| Potassium Chloride | 64 | $1,629 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 42 | $1,197 |
| Rosuvastatin Calcium | 82 | $1,155 |
| Ranolazine ErRanolazine | 18 | $1,069 |
| Propranolol Hcl ErPropranolol Hcl | 12 | $931 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 60 | $925 |
| Losartan Potassium | 115 | $897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $82 | $112,858151 claims |
| Boehringer IngelheimJardiance | $197 | $56,45558 claims |
| Johnson & JohnsonXarelto | $146 | $39,59348 claims |
| NovartisEntresto | $56 | $27,51430 claims |
| AstraZenecaBrilinta | $228 | $5,91413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Michigan City
- Sammi DaliMichigan City$17K
- James HermillerIndianapolis$2.8M
- Jithendra ChoudaryRichmond$1.6M
- Jeffrey BreallIndianapolis$955K
- Samer AbbasEast Chicago$625K
- Jarrod FrizzellEvansville$559K
- Brian BigelowIndianapolis$444K
- Saeed ShaikhIndianapolis$366K
- Dean FerreraEast Chicago$298K
- Woodrow CoreyIndianapolis$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.